Brazzaville, 24 April 2017 - The World Health Organization Regional Office for Africa (WHO/AFRO) announced today that Ghana, Kenya, and Malawi will take part in a WHO-coordinated pilot implementation programme that will make the world’s first malaria vaccine available in selected areas, beginning in 2018. 

The injectable vaccine, RTS,S, was developed to protect young children from the most deadly form of malaria caused by Plasmodium falciparum. RTS,S will be assessed in the pilot programme as a complementary malaria control tool that could potentially be added to the core package of WHO-recommended measures for malaria prevention.

“The prospect of a malaria vaccine is great news. Information gathered in the pilot will help us make decisions on the wider use of this vaccine”, said Dr Matshidiso Moeti, WHO Regional Director for Africa. “Combined with existing malaria interventions, such a vaccine would have the potential to save tens of thousands of lives in Africa,” she added.

Africa bears the greatest burden of malaria worldwide. Global efforts in the last 15 years have led to a 62 percent reduction in malaria deaths between 2000 and 2015, yet approximately 429,000 people died of the disease in 2015, the majority of them young children in Africa.

The WHO pilot programme will assess whether the vaccine’s protective effect in children aged 5 – 17 months old during Phase III testing can be replicated in real-life. Specifically, the pilot programme will assess the feasibility of delivering the required four doses of RTS,S, the vaccine’s potential role in reducing childhood deaths, and its safety in the context of routine use.

WHO recommendations and RTS,S

RTS,S was developed by GSK and is the first malaria vaccine to have successfully completed a Phase III clinical trial. The trial was conducted between 2009 and 2014 through a partnership involving GSK, the PATH Malaria Vaccine Initiative (with support from the Bill & Melinda Gates Foundation), and a network of African research sites in seven African countries—including Ghana, Kenya, and Malawi.

RTS,S is also the first malaria vaccine to have obtained a positive scientific opinion from a stringent medicines regulatory authority, the European Medicines Agency (EMA), which  approved RTS,S  in July 2015.

In October 2015, two independent WHO advisory groups, comprised of the world’s foremost experts on vaccines and malaria, recommended pilot implementation of RTS,S in three to five settings in sub-Saharan Africa. The recommendation came from the Strategic Advisory Group of Experts (SAGE) on Immunization and the Malaria Policy Advisory Committee (MPAC), following a joint review of all available evidence on the vaccine’s safety and efficacy. The World Health Organization formally adopted the recommendation in January 2016.

Pilot implementation

The three countries were selected to participate in the pilot based on the following criteria: high coverage of long-lasting insecticidal-treated nets (LLINs); well-functioning malaria and immunisation programmes, a high malaria burden even after scale-up of LLINs, and participation in the Phase III RTS,S malaria vaccine trial. Each of the three countries will decide on the districts and regions to be included in the pilots. High malaria burden areas will be prioritized, as this is where the benefit of the vaccine is predicted to be highest. Information garnered from the pilot will help to inform later decisions about potential wider use of the vaccine.

The malaria vaccine will be administered via intramuscular injection and delivered through the routine national immunization programmes.  WHO is working with the three countries to facilitate regulatory authorization of the vaccine for use in the pilots through the African Vaccine Regulatory Forum (AVAREF).  Regulatory support will also include measures to enable the appropriate safety monitoring of the vaccine and rigorous evaluation for eventual large scale use.

Gavi, the Vaccine Alliance, the Global Fund to Fight AIDS, Tuberculosis and Malaria, and UNITAID, are partnering to provide US$49.2 million for the first phase of the pilot programme (2017-2020) which will be complemented by in-kind contributions from WHO and GSK.  

_______________________________________________________

For more information, please contact:

Dr Jackson Sillah, Medical Officer (Congo), Tel: +472 413 9370, Mobile:+ 22670356120, Email: sillahj [at] who.int (sillahj[at]who[dot]int)

Dr. Dicky Akanmori, Technical Officer (Congo), Tel: +47 24139112 Mobile: +242 057548343, Email: akanmorid [at] who.int (akanmorid[at]who[dot]int)

Dr Nathan Bakyaita,  Malaria Adviser (Kenya), Tel: +254-20  2717902, Mobile: +254 708 433491,Email: bakyaitan [at] who.int (bakyaitan[at]who[dot]int)

Mary J. Hamel, Senior Technical Officer, Initiation for Vaccine Research & Coordinator for the RTS,S Malaria Vaccine Implementation Programme, GMP,Tel: +41 22791157; Mobile: +41 79 751 6193 Email - Hamelm [at] who.int (Hamelm[at]who[dot]int)

Jemina Mwakisha, Communication & Social Mobilization,(Kenya) Tel:+ 254 710 149489,  Email: mwakishaj [at] who.int (mwakishaj[at]who[dot]int)

C. Boakye-Agyemang, Communications Adviser (Congo), Telephone: +47-241-39420 Mobile: +242 065 20 6565, Email: boakyeagyemangc [at] who.int (boakyeagyemangc[at]who[dot]int)

Christian Lindmeier, Communications Officer (Switzerland) Tel: +41 22 791 1948, Mobile: +41 795 006 552,E-mail: lindmeierch [at] who.int (lindmeierch[at]who[dot]int)